Solasia acquires episil oral liquid business from Camurus
Lund, Sweden and Tokyo, Japan — 8 July 2022 — Camurus AB (NASDAQ STO: CAMX, hereinafter “Camurus”) and Solasia Pharma K.K. (TSE: 4597, hereinafter “Solasia”) today jointly announced that they have entered into an agreement in which Solasia has acquired episil[®] oral liquid (episil, SP-03, hereinafter “episil”), a unique and effective treatment for intra-oral pain associated with e.g. oral mucositis, from Camurus and been granted relevant IP rights. Under the terms of the agreement, Solasia has obtained the assets and relevant worldwide licensing rights to continue developing,